When is the time right for a Phase III clinical study in spinal cord injury (P: 0.05)? by Kramer, John L. K. & Curt, Armin
BRAIN
A JOURNAL OF NEUROLOGY
LETTER TO THE EDITOR
When is the time right for a Phase III clinical study in spinal cord injury (P = 0.05)?
John L. K. Kramer and Armin Curt
Spinal Cord Injury Centre, University Hospital Balgrist, University of Zurich, Zurich, Switzerland
Correspondence to: Armin Curt,
Department of Medicine,
University Hospital Balgrist,
University of Zurich,
Zurich, Forchstrasse 340,
CH 8008 Zurich, Switzerland
E-mail: armin.curt@balgrist.ch
Sir, it was a great pleasure to read the findings from a completed
Phase II minocycline study in acute spinal cord injury recently
published in Brain (Casha et al., 2012). In light of the fact that
there are currently no available neuroprotective treatment options
for individuals with acute spinal cord injury, it was encouraging to
find that minocycline can be feasibly administered in a short time-
frame after injury (12 h) and is safe at therapeutic concentrations.
However, Casha et al.’s (2012) conclusion to enter a pivotal Phase
III trial warrants further discussion.
After stratifying for injury heterogeneity (i.e. complete and in-
complete injuries, cervical and thoracic levels) and different treat-
ment groups (i.e. high and low concentrations), Phase II clinical
trials in spinal cord injury are generally underpowered statistically
to measure significant therapeutic effects. To account for the vari-
ability introduced by small sample sizes, historical data (i.e. based
on findings of well-controlled databases comprising neurological
outcomes acquired during the transition from acute to chronic
spinal cord injury) could be of value to appreciate the meaning
of changes in early phases of clinical study. In individuals with
severe incomplete cervical spinal cord injury [Abbreviated Injury
Scale (AIS0 C)], recent estimates of motor recovery range on aver-
age from 43 (Curt et al., 2008) to 46 points (Marino et al., 2011).
Attributable to a ceiling effect, individuals with less severe incom-
plete spinal cord injury (AIS D) actually recover fewer motor points
(20) (Curt et al., 2008; Marino et al., 2011). Thus, while a 48–
50 motor point change in the motor-incomplete cervical spinal
cord injury group treated with minocycline (80% of whom were
AIS C) is slightly higher than historical control values, it is well
within the expected high degree of variability introduced by the
low number of subjects (n = 5). Furthermore, the difference
between minocycline and placebo may have been exaggerated
by the fact that individuals receiving placebo recovered so few
motor points spontaneously—a finding potentially related to a
high proportion of AIS D subjects in this group.
We remain optimistic that minocycline may be a viable option
for neuroprotection in acute spinal cord injury. However, given the
detrimental impact of another failed Phase III study in the field of
spinal cord injury, and the available evidence, it may be premature
to consider minocycline ready for a multicentre, pivotal trial.
Rather, the next step should be to optimize patient stratification
to reflect where the benefit of minocycline may be most readily
detected.
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